PT3580220T - Aminotriazolopiridinas como inibidores de quinase - Google Patents

Aminotriazolopiridinas como inibidores de quinase

Info

Publication number
PT3580220T
PT3580220T PT187074984T PT18707498T PT3580220T PT 3580220 T PT3580220 T PT 3580220T PT 187074984 T PT187074984 T PT 187074984T PT 18707498 T PT18707498 T PT 18707498T PT 3580220 T PT3580220 T PT 3580220T
Authority
PT
Portugal
Prior art keywords
aminotriazolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
PT187074984T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3580220T publication Critical patent/PT3580220T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT187074984T 2017-02-13 2018-02-12 Aminotriazolopiridinas como inibidores de quinase PT3580220T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13

Publications (1)

Publication Number Publication Date
PT3580220T true PT3580220T (pt) 2022-01-03

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187074984T PT3580220T (pt) 2017-02-13 2018-02-12 Aminotriazolopiridinas como inibidores de quinase

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2902676T3 (es) * 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
MX2020003706A (es) * 2017-10-30 2020-07-22 Bristol Myers Squibb Co Aminoimidazopiridazinas como inhibidores de cinasa.
CA3088548A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR20210019581A (ko) 2018-07-09 2021-02-22 리버 인스티튜트, 아이엔씨 Nav1.8을 억제하기 위한 피리딘 카르복스아미드 화합물
CA3105748A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
BR112021004310A2 (pt) 2018-09-13 2021-05-25 Bristol-Myers Squibb Company indazolcarboxamidas como inibidores de cinase
BR112021004385A2 (pt) 2018-09-13 2021-07-20 Bristol-Myers Squibb Company 1h-indazol carboxamidas como inibidores de proteína quinase de interação com o receptor 1 (ripk1)
SG11202108064XA (en) * 2019-01-25 2021-08-30 Beijing Scitech Mq Pharmaceuticals Ltd Acylamino bridged heterocyclic compound, and composition and application thereof
AU2020246313B2 (en) * 2019-03-22 2022-08-04 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2021160109A1 (zh) * 2020-02-13 2021-08-19 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物,其制法与医药上的用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
JP7406672B2 (ja) 2021-08-10 2023-12-27 アッヴィ・インコーポレイテッド ニコチンアミド系ripk1阻害剤
TW202345852A (zh) 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014637A (es) 2004-06-25 2007-02-12 Amgen Inc Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
CA2750517A1 (en) 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
CN105246891A (zh) 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
BR112018008765B1 (pt) 2015-11-05 2022-05-24 Sumitomo Chemical Company, Limited Composto heterocíclico condensado, composição e método para o controle de um artrópode nocivo
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
ES2902676T3 (es) * 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
MX2020003706A (es) 2017-10-30 2020-07-22 Bristol Myers Squibb Co Aminoimidazopiridazinas como inhibidores de cinasa.
CA3088548A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
US20220315580A1 (en) 2022-10-06
US10913738B2 (en) 2021-02-09
EP3580220B1 (en) 2021-11-17
KR20190117006A (ko) 2019-10-15
CN110520423B (zh) 2022-08-23
HRP20212000T1 (hr) 2022-04-01
AU2018217488B2 (en) 2021-09-23
US20190389859A1 (en) 2019-12-26
ES2902676T3 (es) 2022-03-29
WO2018148626A1 (en) 2018-08-16
US20250074909A1 (en) 2025-03-06
PL3580220T3 (pl) 2022-02-07
RS62801B1 (sr) 2022-02-28
SI3580220T1 (sl) 2022-01-31
LT3580220T (lt) 2021-12-27
SG11201907335UA (en) 2019-09-27
EA201991915A1 (ru) 2019-12-30
IL268614A (en) 2019-10-31
IL268614B (en) 2021-12-01
MX378515B (es) 2025-03-11
CA3053484A1 (en) 2018-08-16
KR102549952B1 (ko) 2023-06-29
MX2019009555A (es) 2019-10-02
HUE057801T2 (hu) 2022-06-28
MA47460A (fr) 2019-12-18
JP7097373B2 (ja) 2022-07-07
CN110520423A (zh) 2019-11-29
EP3580220A1 (en) 2019-12-18
CY1124978T1 (el) 2023-01-05
JP2020507582A (ja) 2020-03-12
DK3580220T3 (da) 2022-01-10
SMT202200001T1 (it) 2022-03-21
EA039808B1 (ru) 2022-03-16
US12157733B2 (en) 2024-12-03
AU2018217488A1 (en) 2019-10-03
BR112019016635A2 (pt) 2020-04-07

Similar Documents

Publication Publication Date Title
FR24C1016I1 (fr) Inhibiteurs de ret
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
PT3580220T (pt) Aminotriazolopiridinas como inibidores de quinase
PT3788040T (pt) Piridazinonas como inibidores de parp7
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
DK3303334T3 (da) Tyrosinkinasehæmmere
BR112017025542A2 (pt) compostos de naftiridina como inibidores de quinase jak
PT3209656T (pt) Compostos de indol carboxamida úteis como inibidores de quinase
MA42242A (fr) Inhibiteurs de la tyrosine kinase
CL2016002502A1 (es) Inhibidores de biaril cinasa
PT3105226T (pt) Ciclopropilaminas como inibidores de lsd1
DK3442972T3 (da) Bromdomænehæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3347008A4 (en) BETA-Lactamase INHIBITORS
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3681884T3 (da) Rad51-inhibitorer
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
IL269063B (en) Pyrimidopyrimidinones used as wee-1 kinase inhibitors
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3394068A4 (en) TDO2 INHIBITORS
EP3303283A4 (en) Fto inhibitors
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase